Baseline patient and disease characteristics
| Patient characteristics . | Patients (N = 25) . |
|---|---|
| Age, median (range), y | 69.0 (59-84) |
| Female, n (%) | 13 (52.0) |
| Eastern Cooperative Oncology Group performance status, n (%) | |
| 0 | 13 (52.0) |
| 1 | 10 (40.0) |
| 2∗ | 2 (8.0) |
| Time since last ATL treatment, median (range), d | 60.0 (23-1400) |
| Prior lines of therapy, median (range) | 3 (1-8) |
| Prior mogamulizumab therapy, n (%) | |
| Yes | 24 (96.0) |
| No | 1 (4.0) |
| Refractory to mogamulizumab-containing therapy, n (%) | 6 (24.0) |
| Prior lenalidomide therapy, n (%) | |
| Yes | 8 (32.0) |
| No | 17 (68.0) |
| Prior anthracycline-based therapy, n (%) | |
| Yes | 24 (96.0) |
| No | 1 (4.0) |
| Prior HSCT, n (%) | |
| No | 25 (100.0) |
| ATL subtype, n (%) | |
| Acute | 16 (64.0) |
| Lymphoma | 6 (24.0) |
| Unfavorable chronic | 3 (12.0) |
| Patient characteristics . | Patients (N = 25) . |
|---|---|
| Age, median (range), y | 69.0 (59-84) |
| Female, n (%) | 13 (52.0) |
| Eastern Cooperative Oncology Group performance status, n (%) | |
| 0 | 13 (52.0) |
| 1 | 10 (40.0) |
| 2∗ | 2 (8.0) |
| Time since last ATL treatment, median (range), d | 60.0 (23-1400) |
| Prior lines of therapy, median (range) | 3 (1-8) |
| Prior mogamulizumab therapy, n (%) | |
| Yes | 24 (96.0) |
| No | 1 (4.0) |
| Refractory to mogamulizumab-containing therapy, n (%) | 6 (24.0) |
| Prior lenalidomide therapy, n (%) | |
| Yes | 8 (32.0) |
| No | 17 (68.0) |
| Prior anthracycline-based therapy, n (%) | |
| Yes | 24 (96.0) |
| No | 1 (4.0) |
| Prior HSCT, n (%) | |
| No | 25 (100.0) |
| ATL subtype, n (%) | |
| Acute | 16 (64.0) |
| Lymphoma | 6 (24.0) |
| Unfavorable chronic | 3 (12.0) |
One patient had an Eastern Cooperative Oncology Group performance status of 2 at initial screening but advanced to a status of 3 on day 1 cycle 1.